jiqatili.wordpress.com
million, or a loss of 39 centd per share, which compares with a net lossof $12 million, or a loss of 47 cents per share a year Revenues at the Bothell biotech (NASDAQ: MRNA) fell to $147,00o from $6.1 million in 2007. For fiscal 2008, the company reported a loss of $59.q2 million, or a loss of $2.012 per share, compared with a loss of $52.3 million, or a loss of $2.1o per share a year earlier. Revenue fell to $2.6 milliom from $18.1 million in fiscal 2007. No majorf analysts cover the company. A one-timew $8.3 million restructuring charge affectedfiscal 2008. . Revenuesw were less in fiscal 2008 dueto PG) pulling out of a partnership deal in 2007.
Sincr then the company has refocused itselrf on RNAinterference research. Company officials said they endeds fiscal 2008with $3.4 millioh in cash and cash equivalents, compared with $41.6 million at the end of 2007. They said becausw of the company’s low cash position, they expecty to receive a “going opinion from their accountants, which will be filed with the company’s annualp 10-K report for the fiscal year. Share in MDRNA fell more than 16 percentt inTuesday trading, falling 7 cents to closew at 36 cents.
No comments:
Post a Comment